Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Jing Huang, Binghe Xu, Ying Liu, Junxing Huang, Ping Lu, Yi Ba, Lin Wu, Yuxian Bai, Shu Zhang, Jifeng Feng, Ying Cheng, Jie Li, Lu Wen, Xianglin Yuan, Changwu Ma, Chunhong Hu, Qingxia Fan, Xi Wang

ABSTRACT

BACKGROUND: The benefit of systemic treatments in esophageal squamous cell carcinoma (ESCC) which has progressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established. We aimed to compare the efficacy of irinotecan plus S-1 with S-1 monotherapy in recurrent or metastatic ESCC patients who had resistance to platinum- or taxane-based chemotherapy. METHODS: We conducted a prospective randomized, multicenter, open-label, phase 3 trial in 15 centers across China. Eligible patients were adults with histologically confirmed recurrent or metastatic ESCC, and were randomly assigned (ratio, 1:1) to receive either irinotecan plus S-1 (intravenous infusion of irinotecan [160 mg/m2] on day 1 and oral S-1 [80-120 mg] on days 1-10, repeated every 14 days) or oral S-1 monotherapy (80-120 mg/day on days 1-14, repeated every 21 days) using a central computerized minimization procedure. The primary endpoint was progression-free survival (PFS). RESULTS: Between December 23, 2014 and July 25, 2016, we screened 148 patients and randomly assigned 123 patients to receive either irinotecan plus S-1 regimen (n = 61) or S-1 monotherapy (n = 62). After a median follow-up of 29.2 months (95% confidence interval [CI] 17.5-40.9 months), the median PFS was significantly longer in the irinotecan plus S-1 group than in the S-1 monotherapy group (3.8 months [95% CI 2.9-4.3 months] vs. 1.7 months [95% CI 1.4-2.7 months], hazard ratio = 0.58, 95% CI 0.38-0.86, P = 0.006). The objective response rates were 24.6% in the irinotecan plus S-1 group and 9.7% in the S-1 monotherapy group (P = 0.002). The patients in the irinotecan plus S-1 group presented with increased rates of grade 3-4 leukopenia (16.4% vs. 0%), neutropenia (14.8% vs. 1.6%), and nausea (4.9% vs. 0%). No significant difference in grade 3-4 diarrhea and no treatment-related deaths were observed in both groups. CONCLUSIONS: The combination of irinotecan with S-1 was similarly tolerable but significantly prolonged PFS compared to S-1 monotherapy as a second- or third-line treatment in patients with recurrent or metastatic ESCC. Clinical Trial Registration NCT02319187. Registered on December 9, 2014. More... »

PAGES

16

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40880-019-0359-7

DOI

http://dx.doi.org/10.1186/s40880-019-0359-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113179528

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30940189


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Peking Union Medical College Hospital", 
          "id": "https://www.grid.ac/institutes/grid.413106.1", 
          "name": [
            "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No 17 Panjiayuan Nanli, Chaoyang District, 100021, Beijing, P. R. China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huang", 
        "givenName": "Jing", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peking Union Medical College Hospital", 
          "id": "https://www.grid.ac/institutes/grid.413106.1", 
          "name": [
            "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No 17 Panjiayuan Nanli, Chaoyang District, 100021, Beijing, P. R. China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xu", 
        "givenName": "Binghe", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Henan Cancer Hospital", 
          "id": "https://www.grid.ac/institutes/grid.414008.9", 
          "name": [
            "Department of Medical Oncology, Henan Cancer Hospital, 450008, Zhengzhou, Henan, P. R. China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liu", 
        "givenName": "Ying", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Taizhou People's Hospital", 
          "id": "https://www.grid.ac/institutes/grid.479690.5", 
          "name": [
            "Department of Medical Oncology, Taizhou People\u2019s Hospital, 225300, Taizhou, Jiangsu, P. R. China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huang", 
        "givenName": "Junxing", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "First Affiliated Hospital of Xinxiang Medical University", 
          "id": "https://www.grid.ac/institutes/grid.493088.e", 
          "name": [
            "Department of Medical Oncology, First Affiliated Hospital of Xinxiang Medical University, 453100, Xinxiang, Henan, P. R. China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lu", 
        "givenName": "Ping", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tianjin Medical University Cancer Institute and Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411918.4", 
          "name": [
            "Department of Medical Oncology, Tianjin Cancer Hospital, 300060, Tianjin, P. R. China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ba", 
        "givenName": "Yi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hunan Cancer Hospital", 
          "id": "https://www.grid.ac/institutes/grid.410622.3", 
          "name": [
            "Department of Medical Oncology, Hunan Cancer Hospital, 410006, Changsha, Hunan, P. R. China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wu", 
        "givenName": "Lin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Third Affiliated Hospital of Harbin Medical University", 
          "id": "https://www.grid.ac/institutes/grid.412651.5", 
          "name": [
            "Department of Medical Oncology, Harbin Medical University Cancer Hospital, 150040, Harbin, Heilongjiang, P. R. China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bai", 
        "givenName": "Yuxian", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shandong Tumor Hospital", 
          "id": "https://www.grid.ac/institutes/grid.440144.1", 
          "name": [
            "Department of Medical Oncology, Shandong Cancer Hospital, 250117, Jinan, Shandong, P. R. China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Shu", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Jiangsu Cancer Hospital", 
          "id": "https://www.grid.ac/institutes/grid.452509.f", 
          "name": [
            "Department of Medical Oncology, Jiangsu Cancer Hospital, 210009, Nanjing, Jiangsu, P. R. China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Feng", 
        "givenName": "Jifeng", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Jilin Province Tumor Hospital", 
          "id": "https://www.grid.ac/institutes/grid.440230.1", 
          "name": [
            "Department of Medical Oncology, Jilin Cancer Hospital, 130012, Changchun, Jilin, P. R. China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cheng", 
        "givenName": "Ying", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Radiotherapy, Shanxi Cancer Hospital, 030013, Taiyuan, Shanxi, P. R. China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Jie", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Medical Oncology, Shanxi Cancer Hospital, 030013, Taiyuan, Shanxi, P. R. China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wen", 
        "givenName": "Lu", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tongji Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412793.a", 
          "name": [
            "Department of Medical Oncology, Tongji Hospital, 430030, Wuhan, Hubei, P. R. China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yuan", 
        "givenName": "Xianglin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Medical Oncology, Chifeng Municipal Hospital, 024000, Chifeng, Inner Mongolia, P. R. China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ma", 
        "givenName": "Changwu", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Second Xiangya Hospital of Central South University", 
          "id": "https://www.grid.ac/institutes/grid.452708.c", 
          "name": [
            "Department of Oncology, The Second Xiangya Hospital of Central South University, 410011, Changsha, Hunan, P. R. China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hu", 
        "givenName": "Chunhong", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "First Affiliated Hospital of Zhengzhou University", 
          "id": "https://www.grid.ac/institutes/grid.412633.1", 
          "name": [
            "Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, P. R. China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fan", 
        "givenName": "Qingxia", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peking Union Medical College Hospital", 
          "id": "https://www.grid.ac/institutes/grid.413106.1", 
          "name": [
            "Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No 17 Panjiayuan Nanli, Chaoyang District, 100021, Beijing, P. R. China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Xi", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1001/jamaoncol.2016.5688", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000195011"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaoncol.2016.5688", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000195011"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jtho.2016.02.020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013281432"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10147-006-0610-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013357947", 
          "https://doi.org/10.1007/s10147-006-0610-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10147-006-0610-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013357947", 
          "https://doi.org/10.1007/s10147-006-0610-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)70024-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030836859"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-008-0893-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031153823", 
          "https://doi.org/10.1007/s00280-008-0893-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-008-0893-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031153823", 
          "https://doi.org/10.1007/s00280-008-0893-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12032-012-0343-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038826231", 
          "https://doi.org/10.1007/s12032-012-0343-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12032-012-0343-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038826231", 
          "https://doi.org/10.1007/s12032-012-0343-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.36.7599", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039094870"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/coc.0b013e3181bead92", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041003471"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/coc.0b013e3181bead92", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041003471"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/coc.0b013e3181bead92", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041003471"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/1759-7714.12323", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044035480"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdh007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044779901"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000348294", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045869512"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000348294", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045869512"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2011.06.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051799274"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077827111", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077858124", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30181-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084052519"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30181-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084052519"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.74.9846", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092595046"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-17-2439", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100562940"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-17-2439", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100562940"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: The benefit of systemic treatments in esophageal squamous cell carcinoma (ESCC) which has progressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established. We aimed to compare the efficacy of irinotecan plus S-1 with S-1 monotherapy in recurrent or metastatic ESCC patients who had resistance to platinum- or taxane-based chemotherapy.\nMETHODS: We conducted a prospective randomized, multicenter, open-label, phase 3 trial in 15 centers across China. Eligible patients were adults with histologically confirmed recurrent or metastatic ESCC, and were randomly assigned (ratio, 1:1) to receive either irinotecan plus S-1 (intravenous infusion of irinotecan [160\u00a0mg/m2] on day 1 and oral S-1 [80-120\u00a0mg] on days 1-10, repeated every 14\u00a0days) or oral S-1 monotherapy (80-120\u00a0mg/day on days 1-14, repeated every 21\u00a0days) using a central computerized minimization procedure. The primary endpoint was progression-free survival (PFS).\nRESULTS: Between December 23, 2014 and July 25, 2016, we screened 148 patients and randomly assigned 123 patients to receive either irinotecan plus S-1 regimen (n\u2009=\u200961) or S-1 monotherapy (n\u2009=\u200962). After a median follow-up of 29.2\u00a0months (95% confidence interval [CI] 17.5-40.9\u00a0months), the median PFS was significantly longer in the irinotecan plus S-1 group than in the S-1 monotherapy group (3.8\u00a0months [95% CI 2.9-4.3\u00a0months] vs. 1.7\u00a0months [95% CI 1.4-2.7\u00a0months], hazard ratio\u2009=\u20090.58, 95% CI 0.38-0.86, P\u2009=\u20090.006). The objective response rates were 24.6% in the irinotecan plus S-1 group and 9.7% in the S-1 monotherapy group (P\u2009=\u20090.002). The patients in the irinotecan plus S-1 group presented with increased rates of grade 3-4 leukopenia (16.4% vs. 0%), neutropenia (14.8% vs. 1.6%), and nausea (4.9% vs. 0%). No significant difference in grade 3-4 diarrhea and no treatment-related deaths were observed in both groups.\nCONCLUSIONS: The combination of irinotecan with S-1 was similarly tolerable but significantly prolonged PFS compared to S-1 monotherapy as a second- or third-line treatment in patients with recurrent or metastatic ESCC. Clinical Trial Registration NCT02319187. Registered on December 9, 2014.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s40880-019-0359-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1041144", 
        "issn": [
          "1000-467X", 
          "2523-3548"
        ], 
        "name": "Cancer Communications", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "39"
      }
    ], 
    "name": "Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial", 
    "pagination": "16", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40880-019-0359-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113179528"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "4a93646dac4cc441f1d3e1a63bd2173f5ee5a779407da3b45aff32d99f1f1def"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101723675"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30940189"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40880-019-0359-7", 
      "https://app.dimensions.ai/details/publication/pub.1113179528"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-16T06:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000377_0000000377/records_106822_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs40880-019-0359-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40880-019-0359-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40880-019-0359-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40880-019-0359-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40880-019-0359-7'


 

This table displays all metadata directly associated to this object as RDF triples.

264 TRIPLES      21 PREDICATES      46 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40880-019-0359-7 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Ncf52fb09d596414fa4aef5e0aa04e9e9
4 schema:citation sg:pub.10.1007/s00280-008-0893-5
5 sg:pub.10.1007/s10147-006-0610-5
6 sg:pub.10.1007/s12032-012-0343-4
7 https://app.dimensions.ai/details/publication/pub.1077827111
8 https://app.dimensions.ai/details/publication/pub.1077858124
9 https://doi.org/10.1001/jamaoncol.2016.5688
10 https://doi.org/10.1016/j.ejca.2011.06.002
11 https://doi.org/10.1016/j.jtho.2016.02.020
12 https://doi.org/10.1016/s1470-2045(14)70024-5
13 https://doi.org/10.1016/s1470-2045(17)30181-x
14 https://doi.org/10.1093/annonc/mdh007
15 https://doi.org/10.1097/coc.0b013e3181bead92
16 https://doi.org/10.1111/1759-7714.12323
17 https://doi.org/10.1158/1078-0432.ccr-17-2439
18 https://doi.org/10.1159/000348294
19 https://doi.org/10.1200/jco.2011.36.7599
20 https://doi.org/10.1200/jco.2017.74.9846
21 schema:datePublished 2019-12
22 schema:datePublishedReg 2019-12-01
23 schema:description BACKGROUND: The benefit of systemic treatments in esophageal squamous cell carcinoma (ESCC) which has progressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established. We aimed to compare the efficacy of irinotecan plus S-1 with S-1 monotherapy in recurrent or metastatic ESCC patients who had resistance to platinum- or taxane-based chemotherapy. METHODS: We conducted a prospective randomized, multicenter, open-label, phase 3 trial in 15 centers across China. Eligible patients were adults with histologically confirmed recurrent or metastatic ESCC, and were randomly assigned (ratio, 1:1) to receive either irinotecan plus S-1 (intravenous infusion of irinotecan [160 mg/m2] on day 1 and oral S-1 [80-120 mg] on days 1-10, repeated every 14 days) or oral S-1 monotherapy (80-120 mg/day on days 1-14, repeated every 21 days) using a central computerized minimization procedure. The primary endpoint was progression-free survival (PFS). RESULTS: Between December 23, 2014 and July 25, 2016, we screened 148 patients and randomly assigned 123 patients to receive either irinotecan plus S-1 regimen (n = 61) or S-1 monotherapy (n = 62). After a median follow-up of 29.2 months (95% confidence interval [CI] 17.5-40.9 months), the median PFS was significantly longer in the irinotecan plus S-1 group than in the S-1 monotherapy group (3.8 months [95% CI 2.9-4.3 months] vs. 1.7 months [95% CI 1.4-2.7 months], hazard ratio = 0.58, 95% CI 0.38-0.86, P = 0.006). The objective response rates were 24.6% in the irinotecan plus S-1 group and 9.7% in the S-1 monotherapy group (P = 0.002). The patients in the irinotecan plus S-1 group presented with increased rates of grade 3-4 leukopenia (16.4% vs. 0%), neutropenia (14.8% vs. 1.6%), and nausea (4.9% vs. 0%). No significant difference in grade 3-4 diarrhea and no treatment-related deaths were observed in both groups. CONCLUSIONS: The combination of irinotecan with S-1 was similarly tolerable but significantly prolonged PFS compared to S-1 monotherapy as a second- or third-line treatment in patients with recurrent or metastatic ESCC. Clinical Trial Registration NCT02319187. Registered on December 9, 2014.
24 schema:genre research_article
25 schema:inLanguage en
26 schema:isAccessibleForFree true
27 schema:isPartOf N62d1a235cbd44619adfa002f2e258bfd
28 Nfb1e0a50605d4cee8db71c116284bb2a
29 sg:journal.1041144
30 schema:name Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial
31 schema:pagination 16
32 schema:productId N0f0bc300192544128716e5049e2e41c1
33 N37b6a4af8992499abf817771aa829a9f
34 Nd675d1819e9a41deb67116b5bf4854f5
35 Ndfed4db32dc541f3b3c72c8fe59f6b33
36 Nfe1a8f16ddf045c297c878b1f43ccf51
37 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113179528
38 https://doi.org/10.1186/s40880-019-0359-7
39 schema:sdDatePublished 2019-04-16T06:23
40 schema:sdLicense https://scigraph.springernature.com/explorer/license/
41 schema:sdPublisher N66ac91547c4146528acd1843ba1b2991
42 schema:url https://link.springer.com/10.1186%2Fs40880-019-0359-7
43 sgo:license sg:explorer/license/
44 sgo:sdDataset articles
45 rdf:type schema:ScholarlyArticle
46 N0e834fbf132f43ad89478bf4b2a26ceb schema:affiliation https://www.grid.ac/institutes/grid.412633.1
47 schema:familyName Fan
48 schema:givenName Qingxia
49 rdf:type schema:Person
50 N0f0bc300192544128716e5049e2e41c1 schema:name pubmed_id
51 schema:value 30940189
52 rdf:type schema:PropertyValue
53 N1556ed79f57b4b47890eadb22654152d schema:affiliation N7be63f5d07974c65b27375372e1b4df4
54 schema:familyName Li
55 schema:givenName Jie
56 rdf:type schema:Person
57 N242b952722a143a4a329879160412892 schema:affiliation https://www.grid.ac/institutes/grid.440144.1
58 schema:familyName Zhang
59 schema:givenName Shu
60 rdf:type schema:Person
61 N245a613fd32f49c0855df2497ed40284 rdf:first N7449d8c24fc549948620a22933ac60a5
62 rdf:rest Nfe3aa6b124af479daaf89b7055c3875e
63 N24d7e9888214481396b6551e841dc013 schema:affiliation https://www.grid.ac/institutes/grid.413106.1
64 schema:familyName Wang
65 schema:givenName Xi
66 rdf:type schema:Person
67 N27dd5567f1654509a18e9c0c2455b970 rdf:first Nee0459330dbf46048f9bd581bf38fd05
68 rdf:rest N8103f882560045f0bcf4a2f26f88d5b1
69 N2884a49e270c46a0b26c6c08cc150098 schema:name Department of Medical Oncology, Chifeng Municipal Hospital, 024000, Chifeng, Inner Mongolia, P. R. China
70 rdf:type schema:Organization
71 N2ae6e2a48aec425f9bf9dd270add5b6d rdf:first N9fdc61e025954d76a574af0fead401c5
72 rdf:rest Nf4a92302ffa540b2ad4207ab5c37a22a
73 N2f5ea2ce923943bda033226c39ee8058 schema:affiliation https://www.grid.ac/institutes/grid.479690.5
74 schema:familyName Huang
75 schema:givenName Junxing
76 rdf:type schema:Person
77 N3070a7bae6544c9d82be5d654a02e885 rdf:first Na1ff11536da44330b5364eca0cfd7854
78 rdf:rest Nea15c9242e5a48c08d373ef9b925f890
79 N37b6a4af8992499abf817771aa829a9f schema:name readcube_id
80 schema:value 4a93646dac4cc441f1d3e1a63bd2173f5ee5a779407da3b45aff32d99f1f1def
81 rdf:type schema:PropertyValue
82 N3b587d74f18949fe999ed2dc2b3566c8 rdf:first N0e834fbf132f43ad89478bf4b2a26ceb
83 rdf:rest Ne54b4808e989481ab53005b7a14c3928
84 N52e12a4f73384777b84d8ac6b0855e04 rdf:first Nb859cb3f751749c0b5e1eab7162ef427
85 rdf:rest N3070a7bae6544c9d82be5d654a02e885
86 N5959f2c4d5ba4d51bae9bdf0256bffd0 rdf:first Nebfda73e9de3463a97d697eebb9ec429
87 rdf:rest N97b9a83f66304b61ae9aedbaf9a05c3b
88 N5f75da865b524882a50ddefb7875be02 rdf:first Na245143195664009a09003c408495643
89 rdf:rest N5959f2c4d5ba4d51bae9bdf0256bffd0
90 N62d1a235cbd44619adfa002f2e258bfd schema:volumeNumber 39
91 rdf:type schema:PublicationVolume
92 N66ac91547c4146528acd1843ba1b2991 schema:name Springer Nature - SN SciGraph project
93 rdf:type schema:Organization
94 N66c57d0e1a4a4e409af723a07c61ea1b schema:affiliation N2884a49e270c46a0b26c6c08cc150098
95 schema:familyName Ma
96 schema:givenName Changwu
97 rdf:type schema:Person
98 N7032744649fc42afbac0a08753791cd1 rdf:first N66c57d0e1a4a4e409af723a07c61ea1b
99 rdf:rest Nf8409b91a8204542bde26ac72a8056bf
100 N7449d8c24fc549948620a22933ac60a5 schema:affiliation https://www.grid.ac/institutes/grid.414008.9
101 schema:familyName Liu
102 schema:givenName Ying
103 rdf:type schema:Person
104 N7be63f5d07974c65b27375372e1b4df4 schema:name Department of Radiotherapy, Shanxi Cancer Hospital, 030013, Taiyuan, Shanxi, P. R. China
105 rdf:type schema:Organization
106 N8103f882560045f0bcf4a2f26f88d5b1 rdf:first Ne604db366e30494d8140670a3eac2ca9
107 rdf:rest N52e12a4f73384777b84d8ac6b0855e04
108 N8ba63e2536b2490f8a9b750afa88938b schema:name Department of Medical Oncology, Shanxi Cancer Hospital, 030013, Taiyuan, Shanxi, P. R. China
109 rdf:type schema:Organization
110 N8dd4c9d0f16c474ca74927528be8fa9d schema:affiliation https://www.grid.ac/institutes/grid.413106.1
111 schema:familyName Huang
112 schema:givenName Jing
113 rdf:type schema:Person
114 N97b9a83f66304b61ae9aedbaf9a05c3b rdf:first N1556ed79f57b4b47890eadb22654152d
115 rdf:rest N2ae6e2a48aec425f9bf9dd270add5b6d
116 N9fdc61e025954d76a574af0fead401c5 schema:affiliation N8ba63e2536b2490f8a9b750afa88938b
117 schema:familyName Wen
118 schema:givenName Lu
119 rdf:type schema:Person
120 Na1ff11536da44330b5364eca0cfd7854 schema:affiliation https://www.grid.ac/institutes/grid.412651.5
121 schema:familyName Bai
122 schema:givenName Yuxian
123 rdf:type schema:Person
124 Na245143195664009a09003c408495643 schema:affiliation https://www.grid.ac/institutes/grid.452509.f
125 schema:familyName Feng
126 schema:givenName Jifeng
127 rdf:type schema:Person
128 Nae51693a06124c5c8a0527ccfe8d60d6 schema:affiliation https://www.grid.ac/institutes/grid.452708.c
129 schema:familyName Hu
130 schema:givenName Chunhong
131 rdf:type schema:Person
132 Nb859cb3f751749c0b5e1eab7162ef427 schema:affiliation https://www.grid.ac/institutes/grid.410622.3
133 schema:familyName Wu
134 schema:givenName Lin
135 rdf:type schema:Person
136 Nc1aadfaaf7a149acb1de026efe836782 rdf:first Nf8485746559d4d8a840577631a30fec9
137 rdf:rest N245a613fd32f49c0855df2497ed40284
138 Nce1a4f110be943a38a0208fff6d65731 schema:affiliation https://www.grid.ac/institutes/grid.412793.a
139 schema:familyName Yuan
140 schema:givenName Xianglin
141 rdf:type schema:Person
142 Ncf52fb09d596414fa4aef5e0aa04e9e9 rdf:first N8dd4c9d0f16c474ca74927528be8fa9d
143 rdf:rest Nc1aadfaaf7a149acb1de026efe836782
144 Nd675d1819e9a41deb67116b5bf4854f5 schema:name doi
145 schema:value 10.1186/s40880-019-0359-7
146 rdf:type schema:PropertyValue
147 Ndfed4db32dc541f3b3c72c8fe59f6b33 schema:name nlm_unique_id
148 schema:value 101723675
149 rdf:type schema:PropertyValue
150 Ne54b4808e989481ab53005b7a14c3928 rdf:first N24d7e9888214481396b6551e841dc013
151 rdf:rest rdf:nil
152 Ne604db366e30494d8140670a3eac2ca9 schema:affiliation https://www.grid.ac/institutes/grid.411918.4
153 schema:familyName Ba
154 schema:givenName Yi
155 rdf:type schema:Person
156 Nea15c9242e5a48c08d373ef9b925f890 rdf:first N242b952722a143a4a329879160412892
157 rdf:rest N5f75da865b524882a50ddefb7875be02
158 Nebfda73e9de3463a97d697eebb9ec429 schema:affiliation https://www.grid.ac/institutes/grid.440230.1
159 schema:familyName Cheng
160 schema:givenName Ying
161 rdf:type schema:Person
162 Nee0459330dbf46048f9bd581bf38fd05 schema:affiliation https://www.grid.ac/institutes/grid.493088.e
163 schema:familyName Lu
164 schema:givenName Ping
165 rdf:type schema:Person
166 Nf4a92302ffa540b2ad4207ab5c37a22a rdf:first Nce1a4f110be943a38a0208fff6d65731
167 rdf:rest N7032744649fc42afbac0a08753791cd1
168 Nf8409b91a8204542bde26ac72a8056bf rdf:first Nae51693a06124c5c8a0527ccfe8d60d6
169 rdf:rest N3b587d74f18949fe999ed2dc2b3566c8
170 Nf8485746559d4d8a840577631a30fec9 schema:affiliation https://www.grid.ac/institutes/grid.413106.1
171 schema:familyName Xu
172 schema:givenName Binghe
173 rdf:type schema:Person
174 Nfb1e0a50605d4cee8db71c116284bb2a schema:issueNumber 1
175 rdf:type schema:PublicationIssue
176 Nfe1a8f16ddf045c297c878b1f43ccf51 schema:name dimensions_id
177 schema:value pub.1113179528
178 rdf:type schema:PropertyValue
179 Nfe3aa6b124af479daaf89b7055c3875e rdf:first N2f5ea2ce923943bda033226c39ee8058
180 rdf:rest N27dd5567f1654509a18e9c0c2455b970
181 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
182 schema:name Medical and Health Sciences
183 rdf:type schema:DefinedTerm
184 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
185 schema:name Oncology and Carcinogenesis
186 rdf:type schema:DefinedTerm
187 sg:journal.1041144 schema:issn 1000-467X
188 2523-3548
189 schema:name Cancer Communications
190 rdf:type schema:Periodical
191 sg:pub.10.1007/s00280-008-0893-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031153823
192 https://doi.org/10.1007/s00280-008-0893-5
193 rdf:type schema:CreativeWork
194 sg:pub.10.1007/s10147-006-0610-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013357947
195 https://doi.org/10.1007/s10147-006-0610-5
196 rdf:type schema:CreativeWork
197 sg:pub.10.1007/s12032-012-0343-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038826231
198 https://doi.org/10.1007/s12032-012-0343-4
199 rdf:type schema:CreativeWork
200 https://app.dimensions.ai/details/publication/pub.1077827111 schema:CreativeWork
201 https://app.dimensions.ai/details/publication/pub.1077858124 schema:CreativeWork
202 https://doi.org/10.1001/jamaoncol.2016.5688 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000195011
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1016/j.ejca.2011.06.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051799274
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1016/j.jtho.2016.02.020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013281432
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1016/s1470-2045(14)70024-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030836859
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1016/s1470-2045(17)30181-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1084052519
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1093/annonc/mdh007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044779901
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1097/coc.0b013e3181bead92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041003471
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1111/1759-7714.12323 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044035480
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1158/1078-0432.ccr-17-2439 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100562940
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1159/000348294 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045869512
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1200/jco.2011.36.7599 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039094870
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1200/jco.2017.74.9846 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092595046
225 rdf:type schema:CreativeWork
226 https://www.grid.ac/institutes/grid.410622.3 schema:alternateName Hunan Cancer Hospital
227 schema:name Department of Medical Oncology, Hunan Cancer Hospital, 410006, Changsha, Hunan, P. R. China
228 rdf:type schema:Organization
229 https://www.grid.ac/institutes/grid.411918.4 schema:alternateName Tianjin Medical University Cancer Institute and Hospital
230 schema:name Department of Medical Oncology, Tianjin Cancer Hospital, 300060, Tianjin, P. R. China
231 rdf:type schema:Organization
232 https://www.grid.ac/institutes/grid.412633.1 schema:alternateName First Affiliated Hospital of Zhengzhou University
233 schema:name Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, P. R. China
234 rdf:type schema:Organization
235 https://www.grid.ac/institutes/grid.412651.5 schema:alternateName Third Affiliated Hospital of Harbin Medical University
236 schema:name Department of Medical Oncology, Harbin Medical University Cancer Hospital, 150040, Harbin, Heilongjiang, P. R. China
237 rdf:type schema:Organization
238 https://www.grid.ac/institutes/grid.412793.a schema:alternateName Tongji Hospital
239 schema:name Department of Medical Oncology, Tongji Hospital, 430030, Wuhan, Hubei, P. R. China
240 rdf:type schema:Organization
241 https://www.grid.ac/institutes/grid.413106.1 schema:alternateName Peking Union Medical College Hospital
242 schema:name Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No 17 Panjiayuan Nanli, Chaoyang District, 100021, Beijing, P. R. China
243 rdf:type schema:Organization
244 https://www.grid.ac/institutes/grid.414008.9 schema:alternateName Henan Cancer Hospital
245 schema:name Department of Medical Oncology, Henan Cancer Hospital, 450008, Zhengzhou, Henan, P. R. China
246 rdf:type schema:Organization
247 https://www.grid.ac/institutes/grid.440144.1 schema:alternateName Shandong Tumor Hospital
248 schema:name Department of Medical Oncology, Shandong Cancer Hospital, 250117, Jinan, Shandong, P. R. China
249 rdf:type schema:Organization
250 https://www.grid.ac/institutes/grid.440230.1 schema:alternateName Jilin Province Tumor Hospital
251 schema:name Department of Medical Oncology, Jilin Cancer Hospital, 130012, Changchun, Jilin, P. R. China
252 rdf:type schema:Organization
253 https://www.grid.ac/institutes/grid.452509.f schema:alternateName Jiangsu Cancer Hospital
254 schema:name Department of Medical Oncology, Jiangsu Cancer Hospital, 210009, Nanjing, Jiangsu, P. R. China
255 rdf:type schema:Organization
256 https://www.grid.ac/institutes/grid.452708.c schema:alternateName Second Xiangya Hospital of Central South University
257 schema:name Department of Oncology, The Second Xiangya Hospital of Central South University, 410011, Changsha, Hunan, P. R. China
258 rdf:type schema:Organization
259 https://www.grid.ac/institutes/grid.479690.5 schema:alternateName Taizhou People's Hospital
260 schema:name Department of Medical Oncology, Taizhou People’s Hospital, 225300, Taizhou, Jiangsu, P. R. China
261 rdf:type schema:Organization
262 https://www.grid.ac/institutes/grid.493088.e schema:alternateName First Affiliated Hospital of Xinxiang Medical University
263 schema:name Department of Medical Oncology, First Affiliated Hospital of Xinxiang Medical University, 453100, Xinxiang, Henan, P. R. China
264 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...